• Suspended

NCT03752541: Allogeneic T-cells with Anti-BCMA CAR - BCMA-UCART in RRMM - Chinese study

Updated: May 28

NCT03752541: Efficacy and Safety Evaluation of BCMA-UCART


AllogeneicT-cells with Anti-BCMA CAR

Chimeric Antigen Receptor)in the Treatment of Relapsed or Refractory Multiple Myeloma


This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with relapsed or refractory multiple myeloma.


Sponsor

Bioray Laboratories


Collaborators

Shanghai Tongji Hospital, Tongji University School of Medicine

Second Xiangya Hospital of Central South University

 

ClinicalTrials.gov Identifier: NCT03752541


Efficacy and Safety Evaluation of BCMA-UCART(Allogeneic Engineered T-cells Expressing Anti-BCMA Chimeric Antigen Receptor)in the Treatment of Relapsed or Refractory Multiple Myeloma


First Posted : November 26, 2018


Click here for details on ClinicalTrials.gov

 

CART - BCMA : National Cancer Institute

Biological: BCMA-UCART

 

Location

China, Shanghai

Shanghai Tongji Hospital


Posts Archive